Avalo Therapeutics (AVTX) CFO awarded 105,000 stock options as equity compensation

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Sullivan Christopher Ryan reported acquisition or exercise transactions in this Form 4 filing.

Avalo Therapeutics reported that its Chief Financial Officer, Christopher Ryan Sullivan, received a grant of stock options representing 105,000 shares of common stock. These options were awarded on February 26, 2026 as an equity-based compensation grant.

The stock option vests 25% on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, conditioned on his continued service. After this grant, Sullivan held 105,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sullivan Christopher Ryan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	105,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 105,000 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/02/2026 - 04:22 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sullivan Christopher Ryan

(Last)

(First)

(Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE

19087

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$17.64	02/26/2026		A		105,000		⁽¹⁾	02/26/2036	Common Stock	105,000	$0	105,000	D

Explanation of Responses:

1. The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.

	/s/ Christopher Sullivan	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Avalo Therapeutics (AVTX) report for its CFO?

Avalo Therapeutics reported that CFO Christopher Ryan Sullivan received a grant of 105,000 stock options on February 26, 2026. This equity award increases his potential future ownership, aligning his incentives with the company’s long-term performance.

How many Avalo Therapeutics (AVTX) stock options were granted to the CFO?

The CFO, Christopher Ryan Sullivan, was granted stock options for 105,000 shares of Avalo Therapeutics common stock. These options were awarded as a compensation grant and are subject to a multi-year vesting schedule linked to his continued service.

When do the newly granted Avalo Therapeutics (AVTX) options vest for the CFO?

Twenty-five percent of the stock options vest on February 26, 2027, with the remaining options vesting in equal monthly installments over the following three years. All vesting is contingent on the CFO’s continued service with Avalo Therapeutics.

What type of security did Avalo Therapeutics (AVTX) grant to its CFO?

Avalo Therapeutics granted its CFO a stock option, defined as a right to buy common shares in the future. The option represents 105,000 underlying shares and is structured as a long-term equity incentive award with staged vesting.

How many Avalo Therapeutics (AVTX) options does the CFO hold after this grant?

Following this award, the Form 4 shows the CFO holding 105,000 stock options directly. This total reflects the newly granted options and represents his reported derivative holdings after the February 26, 2026 equity grant.

Is the Avalo Therapeutics (AVTX) CFO’s option grant immediately exercisable?

The option grant is not fully exercisable immediately. Only 25% vests on February 26, 2027, with the remainder vesting in equal monthly installments over the next three years, all subject to his continued service with the company.